RIGL: Summary for Rigel Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 3:37am EST - Canadian Markets open in 5 hours and 53 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Rigel Pharmaceuticals, Inc. (RIGL)

On Feb 9: 9.09 USD 0.00 (0.00%)

MORE ON RIGL

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Rigel Pharmaceuticals, Inc. (NGM:RIGL) Delayed quote data

Last Trade:	9.09 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	9.09
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	29.83

Day's Range:	N/A - N/A
52wk Range:	4.19 - 14.75
Volume:	0
Avg Vol (3m):	597,165
Market Cap:	471.05M
P/E (ttm):	N/A
EPS (ttm):	-2.58
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add RIGL to Portfolio

Download Data

HEADLINES

•	Rigel to Present at BIO CEO & Investor Conference
	PRNewswire (Fri, Feb 5)

•	2010 Health Care Stock Winners With Or Without Congressional Legislation
	Wall Street Transcript (Wed, Jan 27)

•	Molecular Diagnostics And Point Of Care Diagnostics Companies Lead Buy List From Bleichroeder For 2010
	Wall Street Transcript (Mon, Jan 25)

•	The Technical Indicator: S&P 500 clears major technical hurdle
	at MarketWatch (Tue, Jan 5)

•	Analysts Name Top Biotech Stocks for 2010: BioBuzz
	at TheStreet.com (Tue, Jan 5)

•	Rigel gets milestone payment from Daiichi Sankyo
	AP (Wed, Dec 23)

•	Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target
	PRNewswire (Wed, Dec 23)

•	Rigel Pharma Gives Up Gains
	at Barrons.com (Mon, Dec 21)

•	Generic Drugs Continue To Accelerate Market Share Expansion According To Sanford Bernstein
	Wall Street Transcript (Mon, Dec 7)

•	Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting
	PRNewswire (Tue, Dec 1)

•	Rigel shares rise on RBC analyst upgrade
	AP (Mon, Nov 23)

More Headlines for RIGL...

ANALYST

EPS Est (next year) (Dec-07) :	-2.28
EPS Est (in 2 years) (Dec-08) :	-2.27
Avg Rec (current)*:	1.8
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•